Document is current
Any future updates will be listed below
-
Authors
Kerola, Anne M.
Juonala, Markus
Kytö, Ville
-
Funding
Funding for this research was provided by:
Sydäntutkimussäätiö
Finnish Governmental VTR funding
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 20 October 2024
First Online: 30 October 2024
Declarations
:
: The data were obtained from Findata, including the CRHC data, antidiabetic medication purchase data prior to MI, special reimbursement entitlement data, and cancer data in the Finnish Cancer Registry (permission THL/164/14.02.00/2021); mortality data were obtained from Statistics Finland (permission TK-53-484-20). The included registries are mandatory by law and cover the entire Finnish population. Ethical board review and informed consent were waived by law due to the study design. The participants were not contacted. The legal basis for the processing of personal data is of public interest and scientific research (EU General Data Protection Regulation [GDPR] 2016/679, Article 6(1)I and Article 9(2)(j); Data Protection Act, Sects. 4 and 6).
: Not applicable.
: AMK has received speaker fees from Boehringer-Ingelheim, Abbvie, and Sanofi; has participated in the advisory boards of Pfizer and Boehringer-Ingelheim; and has received congress sponsorship from Abbvie and Johnson & Johnson, which are all unrelated to this work. MJ has received speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Novartis, and NovoNordisk. VK: None.
